Showing content from https://pubmed.ncbi.nlm.nih.gov/33952342/ below:
National genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis protocol
doi: 10.1186/s13643-021-01686-6. National genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis protocol
Affiliations
Affiliations
- 1 Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan. mpalmer@ncc.go.jp.
- 2 Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia. mpalmer@ncc.go.jp.
- 3 Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
- 4 Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- 5 Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
- 6 St Luke's International University, Global Health Nursing, Tokyo, Japan.
- 7 Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
- 8 VCS Population Health, VCS Foundation, East Melbourne, Australia.
Item in Clipboard
National genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis protocol
Matthew Palmer et al. Syst Rev. 2021.
doi: 10.1186/s13643-021-01686-6. Affiliations
- 1 Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan. mpalmer@ncc.go.jp.
- 2 Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia. mpalmer@ncc.go.jp.
- 3 Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
- 4 Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- 5 Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
- 6 St Luke's International University, Global Health Nursing, Tokyo, Japan.
- 7 Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
- 8 VCS Population Health, VCS Foundation, East Melbourne, Australia.
Item in Clipboard
Abstract
Background: Despite prophylactic human papillomavirus (HPV) vaccination being a safe, effective and cost-effective public health intervention for the prevention of cervical cancer, the HPV vaccine is not actively recommended or promoted by the Ministry of Health Labour and Welfare in Japan. With already very low levels of cervical screening below 30%, and vaccination levels that are below levels that award any population effect at 0.3% of the eligible population, cervical cancer mortality is higher than other similar high-income countries at 4.4/100,000 (2900) deaths per year in 2015. There is limited population-based or nationally representative data for HPV genotype distribution in Japan, thus making an assessment of the burden of vaccine-preventable cervical cancer difficult. Therefore, this systematic review and meta-analysis aims to determine the HPV genotype prevalence and age distribution of HPV infection in women with a cytological or histological diagnosis of normal through cervical cancer in Japan. We anticipate this information will guide and enhance programme interventions to reduce vaccine-preventable cervical cancer mortality in Japan.
Methods: PubMed, Embase and the Japan Medical Abstract Society Database will be searched from the date of establishment to March 2021 to identify original research articles that report the prevalence of HPV genotypes in Japanese women with normal cervical cytology, low grade, high grade and cancerous cervical lesions. No exclusion criteria relating to language or publication date will be applied. The quality of the studies will be assessed using the Joanna Briggs checklist for prevalence studies. Randomised control trials, cohort studies, cross-sectional and prevalence studies will be considered eligible. Study findings will be combined using a traditional random-effects or fixed-effects meta-analysis to summarise pooled prevalence and 95% confidence intervals depending on heterogeneity. Subgroup analyses and meta-regression will be used to investigate heterogeneity, and sensitivity analyses will be conducted to assess the robustness of the findings.
Discussion: To our knowledge, this is the first systematic review protocol that includes both Japanese and English peer-reviewed articles for the determination of genotype-specific HPV prevalence in cytological or histological confirmed normal cervical specimens, low- and high-grade intraepithelial lesions and cervical cancers by age in Japan. We anticipate this information will guide and enhance programme interventions to reduce vaccine-preventable cervical cancer mortality in Japan.
Systematic review registration: PROSPERO CRD42018117596.
Keywords: HPV; Human papillomavirus; Japan; Vaccination.
PubMed Disclaimer
Conflict of interest statement
Kota Katanoda has been an expert committee member of the Pharmaceuticals and Medical Devices Agency since 2019. The authors declare that they have no competing interests.
Similar articles
- Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis.
Palmer M, Katanoda K, Saito E, Acuti Martellucci C, Tanaka S, Ikeda S, Sakamoto H, Machelek D, Ml Brotherton J, Hocking JS. Palmer M, et al. Vaccine. 2022 Sep 29;40(41):5971-5996. doi: 10.1016/j.vaccine.2022.07.052. Epub 2022 Sep 6. Vaccine. 2022. PMID: 36085257
- The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. C Kitchener H, et al. Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230. Health Technol Assess. 2014. PMID: 24762804 Free PMC article. Clinical Trial.
- Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.
Kechagias KS, Kalliala I, Bowden SJ, Athanasiou A, Paraskevaidi M, Paraskevaidis E, Dillner J, Nieminen P, Strander B, Sasieni P, Veroniki AA, Kyrgiou M. Kechagias KS, et al. BMJ. 2022 Aug 3;378:e070135. doi: 10.1136/bmj-2022-070135. BMJ. 2022. PMID: 35922074 Free PMC article.
- Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis.
Ogembo RK, Gona PN, Seymour AJ, Park HS, Bain PA, Maranda L, Ogembo JG. Ogembo RK, et al. PLoS One. 2015 Apr 14;10(4):e0122488. doi: 10.1371/journal.pone.0122488. eCollection 2015. PLoS One. 2015. PMID: 25875167 Free PMC article. Review.
- Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L, Hopkins L, Hutton B, Fergusson D. Rambout L, et al. CMAJ. 2007 Aug 28;177(5):469-79. doi: 10.1503/cmaj.070948. Epub 2007 Aug 1. CMAJ. 2007. PMID: 17671238 Free PMC article. Review.
Cited by
- Delay in Diagnosis of Cervical Cancer in Afghanistan: A Pilot Cross-Sectional Survey.
Acuti Martellucci C, Delsoz M, Qaderi S, Madadi S, Bhandari D, Ozaki A, Mousavi SH. Acuti Martellucci C, et al. Front Reprod Health. 2021 Dec 9;3:783271. doi: 10.3389/frph.2021.783271. eCollection 2021. Front Reprod Health. 2021. PMID: 36303966 Free PMC article.
- Prevalence of developmental dyslexia in primary school children: a protocol for systematic review and meta-analysis.
Yang LP, Li CB, Li XM, Zhai MM, Zhao J, Weng XC. Yang LP, et al. World J Pediatr. 2022 Dec;18(12):804-809. doi: 10.1007/s12519-022-00572-y. Epub 2022 Jun 27. World J Pediatr. 2022. PMID: 35759111
References
-
- Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. - DOI - PubMed
-
- de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX, Retrospective International Survey and HPV Time Trends Study Group Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. doi: 10.1016/S1470-2045(10)70230-8. - DOI - PubMed
-
- Bruni LB-RL, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Papillomavirus and related diseases in the world: ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) 2017.
-
- Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GWK, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2(10):868–878. doi: 10.1158/1940-6207.CAPR-09-0031. - DOI - PubMed
-
- Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, de Carvalho NS, Germar MJ, Peters K, Mindel A, de Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99. doi: 10.1016/S1470-2045(11)70286-8. - DOI - PubMed
RetroSearch is an open source project built by @garambo
| Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3